Welcome to our dedicated page for JUPITER NEUROSCIENCES news (Ticker: JUNS), a resource for investors and traders seeking the latest updates and insights on JUPITER NEUROSCIENCES stock.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage pharmaceutical company in Jupiter, Florida, centered on neuroinflammation, central nervous system (CNS) disorders, rare diseases, and healthy aging. Its news flow is anchored by developments around JOTROL™, a patented enhanced resveratrol platform, and the company’s dual-path strategy that spans prescription therapeutics and Nugevia™ longevity supplements.
On this page, readers can follow company announcements about clinical milestones, including progress toward and within the Phase IIa trial of JOTROL™ in Parkinson’s disease and related CNS and rare disease programs such as Alzheimer’s disease, Mucopolysaccharidoses Type I, Friedreich’s ataxia, and MELAS. Updates often highlight preclinical and clinical data on JOTROL™ bioavailability, CNS penetration, and its potential role in addressing neuroinflammation and mitochondrial dysfunction.
Jupiter’s news also covers the commercial build-out of its Nugevia™ product line, including launches of products like GLO, PWR, and MND, the debut of its e-commerce website, and the use of JOTROL™-based formulations to support cognitive resilience, skin vitality, and mitochondrial energy. Press releases describe marketing initiatives, brand ambassador partnerships, and the company’s positioning within the broader longevity and wellness market.
Investors and observers will additionally find coverage of financing transactions such as the Standby Equity Purchase Agreement with an affiliate of Yorkville Advisors, participation in investor conferences, shareholder communications, and regulatory updates including Nasdaq listing matters. For anyone tracking JUNS stock, this news feed provides a centralized view of Jupiter Neurosciences’ scientific, clinical, commercial, and capital markets developments over time.
Jupiter Neurosciences (NASDAQ: JUNS) announced a strategic initiative on January 28, 2026 to expand its Nugevia™ consumer longevity line to support people using GLP-1 weight-loss therapies. The move aligns the company's clinical-stage JOTROL™ platform with a direct-to-consumer longevity business targeting mitochondrial, metabolic, and neuroinflammatory support.
Jupiter cited rising GLP-1 adoption and consumer concerns—including a reported 4,600% spike in searches for “Ozempic face” and reports that significant weight loss may make patients appear up to 5 years older—as rationale for positioning Nugevia™ MND and PWR as complementary products to address related biological stresses.
Jupiter Neurosciences (NASDAQ:JUNS) will present at the 3rd Annual DealFlow Discovery Conference on January 28-29, 2026 at The Borgata Hotel, Casino & Spa in Atlantic City, NJ.
Christer Rosén, Chairman and CEO, will deliver a company presentation and is available for one-on-one investor meetings. Investors can request an investor pass at no cost to attend. More information about the company is available at the company website.
Jupiter Neurosciences (NASDAQ: JUNS) invites investors to an exclusive live webinar on January 6, 2026 at 4:15 p.m. ET, hosted by RedChip Companies. Chairman and CEO Chister Rosén will review Jupiter's resveratrol-based platform JOTROL™, its differentiated bioavailability profile, and plans for an upcoming Phase 2a Parkinson’s disease trial.
The presentation will also cover Jupiter’s dual-path strategy: early commercialization of the Nugevia™ longevity product line and the pharmaceutical development pathway, plus how recent financing supports execution. A live Q&A follows. Registration is free at the RedChip webinar page and questions can be pre-submitted to JUNS@redchip.com.
Jupiter Neurosciences (NASDAQ: JUNS) marked its first full public year by advancing its JOTROL™ program and launching the Nugevia™ consumer brand while strengthening its balance sheet.
Key 2025 milestones: FDA cleared an IND to start a Phase 2a Parkinson’s trial with enrollment planned for early 2026; JOTROL™ showed a reported nine-fold bioavailability plus blood‑brain barrier penetration in preclinical work; Nugevia launched three products with pre-orders and a subscription model; and a strategic financing agreement with Yorkville provides up to $20 million in flexible capital, including an initial pre-paid advance convertible at $1.50.
Jupiter Neurosciences (NASDAQ: JUNS) announced that its management team will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon21) on December 2–3, 2025 in Boca Raton, Florida.
Management will be available for qualified one-on-one investor meetings during the event and investors can schedule meetings by contacting a NobleCon representative or investor relations via JUNS@redchip.com. NobleCon21 is described as a forum for emerging growth companies, investor access, presentations, and networking opportunities.
Jupiter Neurosciences (NASDAQ:JUNS) announced that the FDA cleared its IND to initiate a Phase 2a clinical trial of JOTROL in Parkinson’s disease on November 5, 2025. The clearance enables enrollment for an exploratory Phase 2a study focused on safety and tolerability with secondary PK/PD and biomarker endpoints, and the company expects to begin enrollment in early 2026. Preclinical MPTP-model data showed improved motor endpoints; the company reports its micellar delivery achieves >9-fold higher bioavailability versus traditional resveratrol. Jupiter continues collaboration with Zina Biopharmaceuticals for protocol design and site selection.
Jupiter Neurosciences (NASDAQ: JUNS) entered into financing agreements with an affiliate of Yorkville Advisors providing access to up to $20 million in capital to support its Phase 2 Parkinson’s trial for JOTROL™ and expansion of the Nugevia™ consumer product line. The financing includes a $6 million prepaid advance (initial $4 million funded on Oct 24, 2024) evidenced by convertible promissory notes with a $1.50 fixed conversion price, and a standby equity purchase agreement (SEPA) to sell up to $14 million of common stock over 24 months subject to an effective registration statement. Prepaid advances carry a 7% original issue discount, interest, and 12‑month maturity; SEPA share issuances may be at a 3.0% discount to market. Proceeds will be used for the Phase 2 trial, DTC marketing for Nugevia™, working capital, and general corporate purposes.
Jupiter Neurosciences (NASDAQ:JUNS) has appointed Jean Fallacara, a renowned entrepreneur and neuroscientist, as the third brand ambassador for their consumer longevity supplement line Nugevia™. Fallacara, recognized as one of the "Most Disruptive Entrepreneurs 2023," brings extensive experience in biohacking and biotechnology, including founding Z-Sciences, which was acquired by inTEST Corp in 2021.
Nugevia™ is built on JOTROL™, Jupiter's patented resveratrol-based micellar delivery platform with enhanced bioavailability. The product line includes three formulations: GLO, MND, and PWR, designed to support cellular resilience. This consumer initiative is part of Jupiter's dual-path strategy, targeting the longevity market projected to reach $8 trillion by 2030, while supporting their clinical development programs.
Jupiter Neurosciences (NASDAQ: JUNS) has launched its Nugevia™ e-commerce platform, marking its entry into the $8 trillion global longevity market. The company is now accepting pre-orders for three nutraceutical supplements: Nugevia™ GLO, PWR, and MND, with shipping starting Fall 2025.
The products leverage Jupiter's patented JOTROL™ resveratrol delivery platform, which demonstrated a nine-fold increase in bioavailability in Phase I trials. This launch represents a dual-path business strategy, combining CNS therapeutic development with consumer health products. The company has also secured Hall of Fame golfer Annika Sörenstam and NBA legend Chris Webber as brand ambassadors.
Jupiter Neurosciences (NASDAQ: JUNS) has announced NBA Hall of Famer Chris Webber as the second brand ambassador for their Nugevia™ longevity supplement line. The five-time NBA All-Star will promote the company's science-backed supplements built on the JOTROL™ platform, a patented resveratrol-based micellar delivery system.
The product line features three formulations - GLO, MND, and PWR - designed to enhance cellular resilience through synergistic ingredients optimized for absorption. This consumer initiative is part of Jupiter's dual-path strategy, targeting the $8 trillion longevity market by 2030 while supporting their clinical development programs and operational costs.
FAQ
What is the current stock price of JUPITER NEUROSCIENCES (JUNS)?
What is the market cap of JUPITER NEUROSCIENCES (JUNS)?
